raloxifene hydrochloride has been researched along with Pulmonary Embolism in 8 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (12.50) | 18.2507 |
2000's | 4 (50.00) | 29.6817 |
2010's | 3 (37.50) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Mosekilde, L; Pinholt, EM; Rejnmark, L; Schwartz, K; Vestergaard, P | 1 |
Inoue, D | 1 |
Clarfeld, RB; Costantino, JP; Grant, MD; McCaskill-Stevens, W; Vogel, VG; Wickerham, DL; Wolmark, N | 1 |
Barrett-Connor, E; Cauley, JA; Cox, DA; Geiger, MJ; Kulkarni, PM; Sashegyi, A | 1 |
Fallon, MA; Finkelstein, JS; Lee, H; Smith, MR | 1 |
Adomaityte, J; Farooq, M; Qayyum, R | 1 |
Beitz, J; Brinker, A | 1 |
3 review(s) available for raloxifene hydrochloride and Pulmonary Embolism
Article | Year |
---|---|
[Effects of SERMs on bone health. Raloxifene effects on breast cancer and cardiovascular events].
Topics: Arteriosclerosis; Breast Neoplasms; Female; Humans; Osteoporosis, Postmenopausal; Pulmonary Embolism; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Stroke; Venous Thrombosis | 2010 |
Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Chemoprevention; Clinical Trials as Topic; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Hyperplasia; Incidence; Multicenter Studies as Topic; Pulmonary Embolism; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome | 2010 |
Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis.
Topics: Aged; Bone Density Conservation Agents; Female; Humans; Middle Aged; Odds Ratio; Osteoporosis, Postmenopausal; Patient Selection; Postmenopause; Pulmonary Embolism; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis | 2008 |
2 trial(s) available for raloxifene hydrochloride and Pulmonary Embolism
Article | Year |
---|---|
Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.
Topics: Aged; Breast Neoplasms; Coronary Disease; Double-Blind Method; Female; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Proportional Hazards Models; Pulmonary Embolism; Raloxifene Hydrochloride; Risk Assessment; Stroke; Treatment Outcome | 2004 |
Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial.
Topics: Aged; Biomarkers; Bone Density; Bone Remodeling; Double-Blind Method; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Osteoporosis; Prostatic Neoplasms; Pulmonary Embolism; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Testosterone | 2004 |
3 other study(ies) available for raloxifene hydrochloride and Pulmonary Embolism
Article | Year |
---|---|
Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Denmark; Diphosphonates; Dose-Response Relationship, Drug; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Organometallic Compounds; Osteoporosis; Pulmonary Embolism; Raloxifene Hydrochloride; Thiophenes; Venous Thromboembolism | 2010 |
Tamoxifen for prevention of breast cancer.
Topics: Adult; Breast Neoplasms; Cerebrovascular Disorders; Drug Costs; Endometrial Neoplasms; Estrogen Antagonists; Estrogens; Female; Fractures, Bone; Humans; Middle Aged; Myocardial Infarction; Osteoporosis, Postmenopausal; Piperidines; Placebos; Pulmonary Embolism; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Tamoxifen; Thrombophlebitis | 1999 |
Spontaneous reports of pulmonary embolism in association with raloxifene.
Topics: Adverse Drug Reaction Reporting Systems; Female; Humans; Osteoporosis, Postmenopausal; Pulmonary Embolism; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators | 2001 |